/
REVB
$1.04+$0.06 (+6.12%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.8M
4M shares
52-week range
$0.88 – $12.88
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
71.32%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1715614.96
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $69.2K | $40.0K | $25.0K | $27.9K | $27.1K |
| Gross profit | $0 | $0 | −$69.2K | −$40.0K | −$25.0K | −$27.9K | −$27.1K |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $0 | $2.6M | $6.9M | $5.4M | $4.1M | $3.5M | $4.1M |
| Operating income | −$3.6K | −$3.8M | −$12.0M | −$10.9M | −$8.7M | −$8.0M | −$9.1M |
| EBITDA | −$3.6K | $0 | −$11.9M | −$10.8M | −$8.6M | −$7.9M | −$9.0M |
| Net income | −$3.6K | −$1.6M | −$12.0M | −$10.8M | −$120.3K | −$15.0M | −$8.9M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -6.72 | -9032.69 | -20400.00 | -9643.37 | -8.41 | -87.68 | -23.95 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $49M | $-5.00 | $-5.19–$-4.79 | 2 |
| 2027 | $2M | $-2.77 | $-2.98–$-2.56 | 2 |
| 2028 | $25M | $0.93 | $0.93–$0.93 | 1 |
| 2029 | $55M | $3.03 | $3.03–$3.03 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$15.14
Price
$1.04
Implied upside
+1356%
Peer comparison
Revelation Biosciences, Inc. Common Stock
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
www.revbiosciences.com- Employees
- 9
- IPO / List date
- Jan 11, 2022
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds REVB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in REVB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-28 | 1-for-4reverse |
| 2025-07-07 | 1-for-3reverse |
| 2025-01-28 | 1-for-16reverse |
| 2024-01-25 | 1-for-30reverse |
| 2023-02-01 | 1-for-35reverse |
Recent trades on TradeandTell
No one on the platform has traded REVB yet.
